Background
==========

Severe malaria (SM) caused by *Plasmodium falciparum*results in more than a million deaths each year \[[@B1],[@B2]\]. It is a collection of syndromes that includes cerebral malaria (CM), severe malaria anaemia (SMA), acute respiratory distress syndrome (ARDS), hyperparasitaemia, hypoglycaemia, black water fever, metabolic acidosis, jaundice and renal failure \[[@B1]\]. The reasons why some individuals develop severe complications of malaria, whereas others do not, are still unclear. However, the virulence of the parasite strain causing malaria, as well as the age and genetic background of the infected individual are likely to influence disease outcome.

*Plasmodium falciparum*and humans have had intense interactions for at least 6,000 years and it is thought that malaria has imposed a large selective pressure on the human genome \[[@B3],[@B4]\]. Evidence from both an experimental cerebral malaria (ECM) model \[[@B5]\], as well as from SM patients \[[@B6]-[@B8]\], have identified TNF as an important pro-inflammatory cytokine for the control of infection, and also a strong association with the development of pathology. Single nucleotide polymorphisms (SNPs) within the gene encoding TNF (*TNF*) have been associated with severe outcomes following *Plasmodium*infection in a number of populations in Africa, Asia and the Pacific region \[[@B9]-[@B13]\]. In particular, a SNP in the promoter region of *TNF*at 308 nucleotide base pairs upstream of the transcription start site (-308/376*TNF*) has been reported to confer a greater risk of severe neurological sequelae or death due to CM in the Gambia \[[@B14]\]. This variant was found to be a stronger transcriptional activator than the common allele in some *in vitro*studies \[[@B15]\], but not others \[[@B16]\]. More recent studies examining the MHC class III region, which includes *TNF*as well as the genes encoding the closely related LTα (*LTA*) and LTβ (*LTB*), suggest that positive associations between disease and *TNF*alleles could in fact be due to real disease alleles in neighbouring genes \[[@B17]\]. One such study observed that when specific SNPs were present in TNF, in combination with specific SNPs in *LTA*, *LTA*transcription rather than *TNF*transcription was modulated by changing the way RNA polymerase specifically bound to the *LTA*promoter \[[@B18]\]. Importantly, LTα, not TNF, has been shown to be a critical factor in the development of experimental cerebral malaria in C57BL/6 mice \[[@B19]\], identifying *LTA*along with *TNF*as a candidate susceptibility gene.

Recently, a genome wide association study involving 3 African populations from The Gambia, Kenya and Malawi, investigated potential associations between SM and 8 SNPs spanning the *LTA/TNF*locus \[[@B20]\]. An association was found between *TNF*-238A allele and SM in samples from The Gambia only, and not for any other SNP tested in any of the populations examined \[[@B20]\]. These findings suggested different selective pressures in the *LTA/TNF*locus in different populations, as well as highlighting the need for more-detailed mapping of polymorphisms across this locus to identify causal SNPs associated with SM susceptibility \[[@B20]\]. Here, an extensive analysis was conducted of 35 SNP\'s found in the *LTA/TNF/LTB*gene locus in adults and children of highland Papuan origin, a population not historically exposed to malaria transmission prior to the 1970 s, but who during the study period had been exposed to malaria following migration to the lowland region of Papua.

Methods
=======

Study participants and sample preparation
-----------------------------------------

Characteristics of the study participants upon admission to hospital and controls, including population structure, have been described in Table [1](#T1){ref-type="table"} and the methods section of a recent publication \[[@B21]\]. No corrections were required. Highland Papuan patients with SM and asymptomatic malaria-exposed controls were recruited in a case-control study in Timika, a lowland region of Papua, Indonesia. Genotypes significantly associated with SM in highland Papuans, were also examined in a Tanzanian case-control study comprising children with CM enrolled in Dar es Salaam using WHO criteria as previously described \[[@B22]\] and asymptomatic malaria-exposed, healthy control children from Mikocheni Primary school in the Kinondoni Municipality of the Dar es Salaam region. Written informed consent was obtained from all study subjects or their next of kin, parent or guardian. Studies were approved by the Ethics Committees of the National Institute of Health Research and Development (Ministry of Health, Jakarta, Indonesia), Menzies School of Health Research (Darwin, Australia), Queensland Institute of Medical Research (Brisbane, Australia), Muhimbili University of Health Sciences (Dar es Salaam, Tanzania), National Institute for Medical Research (Dar es Salaam, Tanzania), University of Utah Medical Center (Salt Lake City, USA) and Duke University Medical Center (Durham, USA).

###### 

The SNP set used to investigate the *LTA/TNF/LTB*locus.

  Map Number   db SNP rs    SNP Location    Gene      Role                Polymorphic
  ------------ ------------ --------------- --------- ------------------- -------------
  1            rs2857602    chr6:31641357   LTA       Promoter            Yes
  2            rs2844486    chr6:31641849   LTA       Promoter            No
  3            rs3131637    chr6:31643053   LTA       Promoter            Yes
  4            rs2844484    chr6:31644203   LTA       Promoter            Yes
  5            rs2844483    chr6:31644775   LTA       Promoter            Yes
  6            rs2009658    chr6:31646223   LTA       Promoter            Yes
  7            rs4647191    chr6:31646617   LTA       Promoter            No
  8            rs2844482    chr6:31647746   LTA       Promoter            Yes
  9            rs2071590    chr6:31647747   LTA       Promoter            Yes
  10           rs1800683    chr6:31648050   LTA       Promoter            Yes
  11           rs2239704    chr6:31648120   LTA       Exon                Yes
  12           rs909253     chr6:31648292   LTA       Intron (boundary)   Yes
  13           rs2857713    chr6:31648535   LTA       Coding exon         Yes
  14           rs3093543    chr6:31648736   LTA       Coding exon         No
  15           rs1041981    chr6:31648763   LTA       Coding exon         Yes
  16           rs1799964    chr6:31650287   LTA       3\' UTR             Yes
  17           rs1799724    chr6:31650461   LTA       3\' UTR             Yes
  18           rs1800750    chr6:31650942   TNF       Promoter            No
  19           rs1800629    chr6:31651010   TNF       Promoter            No
  20           rs361525     chr6:31651080   TNF       Promoter            No
  21           rs3179060    chr6:31651651   TNF       Coding exon         No
  22           rs3093661    chr6:31651737   TNF       Intron (boundary)   No
  23           rs1800610    chr6:31651806   TNF       Intron              Yes
  24           rs3093662    chr6:31652168   TNF       Intron              No
  25           rs4645843    chr6:31652541   TNF       Coding exon         No
  26           rs1800620    chr6:31652570   TNF       Intron (boundary)   No
  27           rs3093664    chr6:31652621   TNF       Intron (boundary)   No
  28           rs1800618    chr6:31652897   TNF       Coding exon         No
  29           rs11574936   chr6:31653172   TNF       Coding exon         No
  30           rs3093668    chr6:31654474   TNF       3\' UTR             No
  31           rs3091257    chr6:31654829   TNF       3\' UTR             Yes
  32           rs769178     chr6:31655493   LTB       3\' UTR             Yes
  33           rs769177     chr6:31655590   LTB       3\' UTR             Yes
  34           rs2229699    chr6:31656835   LTB       Exon                No
  35           rs1052248    chr6:31664560   LST1^a^   Exon                Yes

^a^LST1, leukocyte specific transcript 1 (also the 5\' UTR of *LTB*).

Sequencing the LTA gene
-----------------------

The gene encoding LTα, spanning a region of 5323 base pairs (bp) was sequenced in a subset of samples to check for the presence of novel SNPs. The locus was amplified in sections of approximately 500 bp by PCR and sequenced. Sequenced products were aligned against a published human *LTA*sequence \[[@B23]\]. Identified SNPs were also checked on the NCBI website \[[@B24]\] for previous publication.

SNP selection
-------------

*TNF/LTA/LTB*SNPs were included in this study based on reported functional changes (i.e. transcriptional or protein level) or on previous associations with malaria, other infectious diseases, ischaemic stroke, cerebral infarction, atherosclerosis or inflammation \[[@B9]-[@B12],[@B14],[@B18],[@B25]-[@B43]\]. SNPs in the *TNF/LTA/LTB*locus observed to be present in ethnic groups from Sulawesi, an island in the Indonesian archipelago \[[@B44]\], were also included. The final set of polymorphisms included as many functional and disease-associated SNPs as possible following primer design and testing. Tagging SNPs were selected based on reported frequencies in other populations. This SNP set has been described elsewhere \[[@B45]\]. All SNP sequences were obtained from the Chip Bioinformatics database \[[@B46]\] and verified in NCBI.

Genotyping
----------

Assays were designed for thirty-five SNPs across the *TNF/LTA/LTB*region in a multiplex using the Sequenom MassARRAY Assay Design software (version 3.0). SNPs were typed using iPLEX™ chemistry and analyzed using a Sequenom MassARRAY Compact Mass Spectrometer (Sequenom Inc, San Diego, CA, USA). The 2.5 ml PCR reactions were performed in standard 384-well plates using 10 ng genomic DNA, 0.5 unit of Taq polymerase (HotStarTaq, Qiagen), 500 mmol of each dNTP, and 100 nmol of each PCR primer. Standard PCR thermal cycling conditions and post-PCR extension reactions were carried out as described previously \[[@B45]\]. The iPLEX reaction products were desalted and spotted on a SpectroChip (Sequenom). Data were processed and analysed by MassARRAY Workstation (version 3.4) software (Sequenom). Single SNP genotyping specific for rs2071590 and rs1052248 was performed using TaqMan SNP Genotyping Assays according to the manufacturer\'s instructions (Applied Biosystems, Foster City, CA) by using the allelic discrimination on a Corbett RG-6000 (Corbett Life Sciences, Sydney, NSW, Australia) or an AB7900 machine (Applied Biosystems). Previously characterized genotypes for these SNPs were included as positive controls and run alongside samples with unknown genotype.

Statistical analyses
--------------------

Based on our sample size (380 cases and 356 controls), 80% power was available to detect a disease allele with a relative risk of 1.5 at a disease frequency of 0.25. Haploview version 3.32 (Whitehead Institute for Biomedical Research, USA; \[[@B47]\]) was used to perform all statistical tests relating to this SNP analysis \[[@B48]\]. Genotype frequencies of all SNPs were tested for departures from Hardy-Weinberg equilibrium in both cases and controls separately. In the Papuan study, 16 SNPs were found to be non-polymorphic (Table [1](#T1){ref-type="table"}). Haplotype frequencies and linkage disequilibrium (LD) tests were also determined by Haploview version 3.32 \[[@B48]\] using the default method of Gabriel \[[@B49]\]. The association between single markers and haplotype blocks was performed by the Haploview programme. Generated *P*-values for SNPs spanning the *LTA/TNF/LTB*locus were corrected for multiple testing of all the SNPs and haplotype blocks within the region tested through 10,000 permutations. A global P-value of \< 0.05 was considered statistically significant.

Results
=======

LTA/TNF locus is not associated with severe malaria
---------------------------------------------------

In total, 380 SM cases (262 adults and 118 children) and 356 control individuals (305 adults and 51 children) were included in the genotyping study \[[@B21]\]. A subset of the samples was randomly chosen for sequencing of a 5,323 bp region spanning *LTA*, and this revealed no novel SNPs in the study population, and that all SNPs detected in the sequenced *LTA*had previously been reported and, where possible, were included in the SNP set (Table [1](#T1){ref-type="table"}). The SNP set consisted of 35 SNPs that spanned the *LTA/TNF/LTB*locus on chromosome 6 (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). The majority of the samples were successfully genotyped for each of the SNPs with an average coverage of greater than 99%. Of these, 16 SNPs were found to be non-polymorphic (Table [1](#T1){ref-type="table"}). The minor allele frequencies of the remaining SNPs spanning the *LTA/TNF/LTB*locus ranged from 0.001 to 0.44 in control subjects and from 0.001 to 0.49 in patients with SM. Two SNPs, rs2071590 and rs1052248, situated in the *LTA*and *LTB*promoter regions, respectively, showed some differences in allele frequencies between control subjects and SM patients (*P*= 0.034 and *P*= 0.007, respectively). These differences were not observed once corrections were made for multiple testing (global *P*\> 0.05; Table [2](#T2){ref-type="table"}). Analysis of haplotypes did not reveal any association between haplotype blocks and susceptibility to SM (Figure [2](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}).

![**Chromosomal location of SNPs studied in the *LTA/TNF/LTB*locus**. 35 SNPs that cover the *LTA/TNF/LTB*locus on chromosome 6 were analysed in highland Papuans. SNPs selected for study were based on reported functional changes, previous associations with malaria, and other infectious diseases or inflammatory conditions. Certain tagged SNPs were included based on reported frequencies in other populations.](1475-2875-9-302-1){#F1}

###### 

Association analysis of SNPs across the *LTA/TNF/LTB*gene locus genotyped in severe malaria cases and controls.

  --------------------------------------------------------------------------------------------------------------------------
  dbSNP rs    Position        Gene   Role                Alleles   MAF^a^    OR^b^\    Association^d^\   *P-*value   
                                                                             (CI)^c^   χ^2^                          
  ----------- --------------- ------ ------------------- --------- --------- --------- ----------------- ----------- -------
  rs2857602   chr6:31641357   LTA    Promoter            G \> A    0.27      0.27      1.02\             0.02        1.000
                                                                                       (0.81-1.28)                   

  rs3131637   chr6:31643053   LTA    Promoter            A \> T    0.27      0.27      1.02\             0.02        1.000
                                                                                       (0.81-1.28)                   

  rs2844484   chr6:31644203   LTA    Promoter            A \> G    0.27      0.27      1.03\             0.05        1.000
                                                                                       (0.81-1.29)                   

  rs2844483   chr6:31644775   LTA    Promoter            T \> G    0.27      0.27      1.02\             0.02        1.000
                                                                                       (0.81-1.28)                   

  rs2009658   chr6:31646223   LTA    Promoter            C \> G    0.25      0.26      1.05\             0.14        1.000
                                                                                       (0.83-1.33)                   

  rs2844482   chr6:31647746   LTA    Promoter            C \> T    0.25      0.26      1.07\             0.30        1.000
                                                                                       (0.85-1.35)                   

  rs2071590   chr6:31647747   LTA    Promoter            A \> G    0.44      0.49      1.25\             4.52        0.366
                                                                                       (1.02-1.54)                   

  rs1800683   chr6:31648050   LTA    Promoter            G \> A    0.02      0.01      1.98\             1.82        0.979
                                                                                       (0.72-5.35)                   

  rs2239704   chr6:31648120   LTA    Exon                A \> C    0.27      0.27      1.02\             0.03        1.000
                                                                                       (0.81-1.29)                   

  rs909253    chr6:31648292   LTA    Intron (boundary)   A \> G    0.02      0.01      1.98\             1.84        0.978
                                                                                       (0.73-5.36)                   

  rs2857713   chr6:31648535   LTA    Coding exon         T \> C    0.25      0.26      1.06\             0.23        1.000
                                                                                       (0.84-1.34)                   

  rs1041981   chr6:31648763   LTA    Coding exon         C \> A    0.02      0.01      2.15\             2.44        0.814
                                                                                       (0.80-5.77)                   

  rs1799964   chr6:31650287   LTA    3\' UTR             T \> C    0.25      0.27      1.07\             0.30        1.000
                                                                                       (0.84-1.35)                   

  rs1799724   chr6:31650461   LTA    3\' UTR             C \> T    0.43      0.39      1.19\             2.76        0.755
                                                                                       (0.97-1.47)                   

  rs1800610   chr6:31651806   TNF    Intron              G \> A    0.42      0.39      1.13\             1.37        0.992
                                                                                       (0.92 - 1.40)                 

  rs3091257   chr6:31654829   TNF    3\' UTR             C \> A    \< 0.01   \< 0.01   1.07\             \< 0.01     1.000
                                                                                       (0.07 - 17.11)                

  rs769178    chr6:31655493   LTB    3\' UTR             C \> A    0.43      0.39      1.20\             2.98        0.682
                                                                                       (0.97 - 1.49)                 

  rs769177    chr6:31655590   LTB    3\' UTR             G \> A    0.04      0.05      1.11\             0.15        1.000
                                                                                       (0.67 - 1.84)                 

  rs1052248   chr6:31664560   LST1   Exon                A \> T    0.42      0.49      1.33\             7.22        0.098
                                                                                       (1.08 -1.63)                  
  --------------------------------------------------------------------------------------------------------------------------

^a^Minor allele frequency.

^b^Odds ratio.

^c^95% confidence interval.

^d^Association χ^2^with severe malaria.

![**Linkage disequilibrium plot of *LTA/TNF/LTB*SNP set in all severe malaria patients**. The LD plot shading scheme illustrates the estimated LD between the SNPs, and the LD value is displayed within the box. Dark grey regions signify strong LD (1.0), whereas light grey and white regions depict low LD (\< 1.0).](1475-2875-9-302-2){#F2}

###### 

Common haplotype blocks and their association with severe malaria

  -------------------------------------------------
  Haplotype         Frequency\   c^2^   *P-value*
                    (control)           
  ----------------- ------------ ------ -----------
  [Block 1]{.ul}:                       

  GAAT              0.73         0.01   1.000

  ATGG              0.27         0.01   1.000

  [Block 2]{.ul}:                       

  CCAATTTAAA        0.42         1.38   0.992

  GTGCCCCGCT        0.24         0.56   1.000

  CCGATTCGCT        0.17         6.63   0.133

  CCAATTCGCA        0.14         1.64   0.984
  -------------------------------------------------

Next, the *TNF/LTA/LTB*locus was examined to establish whether it was associated with susceptibility to CM in either adults or children. Overall, there were no differences in allele frequencies between control subjects and CM patients (Table [4](#T4){ref-type="table"}). Furthermore, neither age nor susceptibility to CM was associated with the *TNF/LTA/LTB*locus for either single SNPs or haplotype blocks (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). Given the association between the two SNPs situated in the *LTA*and *LTB*promoter regions and SM prior to correcting for multiple testing described above, the association of rs2071590 and rs1052248 in patients originating from and resident in a malaria-endemic region (245 healthy children (HC) and 77 children with CM from Dar es Salaam, Tanzania) was also examined, but no association between these SNPs and CM was found. Taken together, there was no evidence for the *TNF/LTA/LTB*locus contributing to SM or CM in highland Papuans historically not exposed to malaria.

###### 

Lack of association between *LTA/TNF/LTB*SNPs and severe malaria subgroups when compared with adult and childhood controls in the Papuan population.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  dbSNP rs    [All CM]{.ul}\   [Adult SM]{.ul}\   [Adult CM]{.ul}\   [Childhood SM]{.ul}(118)   [Childhood CM]{.ul}(21)                                 
              (106)^a^         (262)              (85)                                                                                                  
  ----------- ---------------- ------------------ ------------------ -------------------------- ------------------------- ------- ------ ------- ------ -------
  rs2857602   0.28             1.000              0.27               1.000                      0.27                      1.000   0.28   0.999   0.26   1.000

  rs3131637   0.28             1.000              0.27               1.000                      0.27                      1.000   0.28   0.999   0.26   1.000

  rs2844484   0.28             1.000              0.27               1.000                      0.27                      1.000   0.28   0.999   0.26   1.000

  rs2844483   0.28             1.000              0.27               1.000                      0.27                      1.000   0.28   0.999   0.26   1.000

  rs2009658   0.25             1.000              0.26               1.000                      0.26                      1.000   0.26   0.951   0.22   0.999

  rs2844482   0.27             1.000              0.26               1.000                      0.26                      1.000   0.26   0.957   0.22   0.999

  rs2071590   0.51             0.841              0.46               0.895                      0.45                      0.963   0.47   0.631   0.44   0.950

  rs1800683   0.01             1.000              0.01               1.000                      0.01                      1.000   0.02   0.488   0.04   1.000

  rs2239704   0.28             1.000              0.27               1.000                      0.27                      1.000   0.28   0.999   0.26   1.000

  rs909253    0.01             1.000              0.01               1.000                      0.01                      1.000   0.02   0.488   0.04   1.000

  rs2857713   0.27             1.000              0.26               1.000                      0.26                      1.000   0.26   0.983   0.23   1.000

  rs1041981   0.01             1.000              0.01               0.999                      0.01                      1.000   0.02   0.488   0.04   1.000

  rs1799964   0.27             1.000              0.26               1.000                      0.26                      1.000   0.26   0.951   0.22   0.999

  rs1799724   0.36             0.597              0.41               0.992                      0.41                      0.869   0.41   0.744   0.45   0.992

  rs1800610   0.36             0.902              0.40               1.000                      0.40                      0.945   0.41   0.828   0.44   0.996

  rs3091257   \-               \-                 \-                 \-                         \-                        \-      \-     \-      \-     \-

  rs769178    0.36             0.581              0.41               0.992                      0.41                      0.851   0.41   0.83    0.44   0.996

  rs769177    0.06             0.983              0.04               1.000                      0.04                      1.000   0.05   1.00    0.06   0.995

  rs1052248   0.50             0.490              0.45               0.543                      0.44                      0.878   0.46   0.26    0.40   0.884
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Number in each group.

^b^MAF - minor allele frequency in cases.

Discussion
==========

Both genetic and serological data indicate roles for TNF and LTα in the pathogenesis of SM \[[@B6]-[@B14],[@B50],[@B51]\]. However, there was a lack of association between SNPs in the *TNF/LTA/LTB*and SM in a highland Papuan population. This lack of association remained following subsequent testing in disease subsets and in both children and adults. *TNF*polymorphisms have been associated with malaria transmission and SM, primarily in populations originating and living in malaria endemic areas \[[@B9]-[@B14]\]. A small number of studies have investigated the relationship between two *LTA*SNPs and malaria. *LTA*C+80A (rs2239704), a SNP that allows specific binding of the transcriptional repressor ABF-1 and, therefore, considered to be a low LTα-producing allele, has been associated with lower *P. falciparum*parasitaemia in malaria-endemic Burkina Faso but was not associated with SM in a case-control study in The Gambia \[[@B40],[@B51],[@B52]\]. *LTA*A+252G (rs909253) has been reported to influence LTα production \[[@B53]\], but this SNP was not associated with SM in Sri Lanka \[[@B9]\]. More recently, rs2239704 and rs909253 were reported to not be associated with SM in a study of SM patients from The Gambia, Kenya and Malawi \[[@B20]\]. Both rs2239704 and rs909253 were included in the present study but not found to be associated with SM. A recent genome wide association study found that only rs2516486 at *TNF*was weakly associated with malaria severity, however the authors caution that the candidate SNPs examined in this study were poorly tagged by the 500 K array used \[[@B54]\].

*LTA*polymorphisms were of particular interest. In highland Papuans (a population without historical exposure to malaria), the minor allele for rs2239704 (Table [3](#T3){ref-type="table"}) is the opposite allele to that observed in a study population from malaria-endemic Burkina Faso \[[@B51]\], suggesting that different pressures may have selected for different alleles in the two populations. Despite two SNPs situated in the *LTA*and *LTB*promoter regions (rs2071590 and rs1052248, respectively), having differences in allele frequencies between control subjects and SM patients, this was not significant after correction for multiple testing, nor was there a difference in the Tanzanian population studied. Thus, our data provide no evidence for an involvement of the *LTA/TNF/LTB*locus in SM susceptibility in highland Papuans, and suggest that if the genes encoded by this locus are involved in SM pathogenesis then molecules that regulate the production and/or bioavailablity may influence disease outcome. Interestingly, an association between susceptibility to SM and a SNP in the LTα-related gene encoding galectin-2 (*LGALS2*) was recently identified. The particular SNP in *LGALS2*is thought to regulate the trafficking of LTα out of cells \[[@B55]\]. Strikingly, the association between *LGALS2*and SM was found to be present in highland Papuan children, but not adults \[[@B21]\]. A further consideration in future studies should be the effects of other genes with important immunological functions in the region surrounding the TNF locus that could contribute to the development of severe malaria. The potential importance of such genes was highlighted in a recent study showing that SNPs in HLA-B associated transcript 2 (*BAT2*) in the MHC III region were associated with severe malaria susceptibility, while *TNF*and *LTA*SNPs were not \[[@B52]\].

Conclusion
==========

It is clear that large, highly powered studies will be necessary to identify causal variants in genes that contribute to SM disease outcome. However, as discussed above, it is likely that different populations have had different selective pressures placed upon them, resulting in a number of susceptibility alleles across different populations. Hence, deep sequencing studies in the *TNF/LTA/LTB*locus of different populations may be warranted and required to identify causal variants in these genes responsible for susceptibility to SM syndromes.
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